Coronary artery surgery for ischemic heart failure: Risks, benefits, and the importance of assessment of myocardial viability

Progress in Cardiovascular Diseases

Volumn 43, Issue 5, 2001, Pages 373-386

  Pitt, Michael ^a   Lewis, Michael E ^a   Bonser, Robert S ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASSISTED CIRCULATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART TRANSPLANTATION; ISCHEMIC HEART DISEASE; MYOCARDIAL HIBERNATION; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0035106091     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2001.20672     Document Type: Article

References (76)

1. Incidence and aetiology of heart failure; A population-based study
2. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam study
3. The epidemiology of heart failure: The Framingham study
4. An overview of contemporary etiologies of congestive heart failure
5. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population
6. Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992
7. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial
8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomised trial
9. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
10. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
11. Ejection fraction, oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure
12. Myocardial reperfusion limitation of infarct size, reduction of left ventricular dysfunction and improved survival. Should the paradigm be expanded
13. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularisation
14. Post-extrasystolic potentiation of ischaemic cardiomyopathy by atrial stimulation
15. The hibernating myocardium
16. Oxygen-derived free radicals and postischaemic myocardial dysfunction "stunned myocardium"
17. Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium)
18. Simultaneous transmission-emission thallium-201 cardiac SPECT: Effect of attenuation correction on myocardial tracer distribution
19. Attenuation-corrected 99m Tc-tetrofosmin single-photon emission computed tomography in the detection of viable myocardium: Comparison with positron emission tomography using 18 F-Fluorodeoxyglucose
20. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography
21. Biphasic response to dobutamine predicts improvement of global left ventricular function after surgical revascularization in patients with stable coronary artery disease - Implications of time course of recovery on diagnostic accuracy
22. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularisation
23. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: Operative technique
24. Results of coronary artery surgery in patients with poor left ventricular function (CASS)
25. Twelve-year follow-up of survival in the randomised European Coronary Surgery Study
26. Eleven-year survival in the veterans administration randomised trial of coronary bypass surgery for stable angina
27. Effect of coronary artery bypass graft on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialist Collaboration
28. Survival in medically treated coronary artery disease
29. Survival of medically treated patients in the Coronary Artery Surgery Study (CASS)
30. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
31. Long-term survival in severe heart failure in patients treated with enalapril; ten year follow-up of CONSENSUS I
32. A perspective on the three large multicenter randomized clinical trials of coronary artery bypass surgery for chronic stable angina
33. A randomised trial of coronary artery bypass surgery. Survival of patients with low ejection fraction
34. Surgical survival benefit for coronary disease patients with left ventricular dysfunction
35. Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function
36. Coronary artery bypass grafting in patients with ejection fractions below forty percent
37. Reversible ischaemic left ventricular dysfunction: Evidence for "hibernating myocardium"
38. Ischaemic cardiomyopathy medical versus surgical treatment
39. Coronary revascularization rather than cardiac transplantation for chronic ischaemic cardiomyopathy
40. Ischaemic cardiomyopathy. Criteria for myocardial revascularisation and cardiac transplantation
41. Coronary artery bypass in patients with severely depressed ventricular function
42. Severe ischaemic left ventricular failure: Coronary operation or heart transplantation?
43. Coronary artery bypass grafting in severe left ventricular dysfunction: Excellent survival with improved ejection fraction and functional state
44. Coronary bypass with ejection fraction of 0.20 or less using centigrade cardioplegia: Long term follow-up
45. Myocardial viability assessment in ischaemic cardiomyopathy: Benefits of coronary revascularisation
46. Results of revascularisation in patients with severe left ventricular dysfunction
47. Improved outcome after coronary artery bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability
48. Hibernating myocardium: Clinical and functional response to revascularisation
49. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease
50. Coronary artery bypass grafting for ischemic heart failure. The predictive value of quantitative PET for symptomatic and functional outcome
51. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: Implications for the role of myocardial viability assessment in management decisions
52. Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction
53. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography
54. Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction
55. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy
56. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction
57. Prevalence of hibernating myocardium in patients with severely impaired ischaemic left ventricles
58. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure
59. Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction
60. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography
61. Coronary revascularisation for postischaemic heart failure: How myocardial viability affects survival
62. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography
63. Delay in revascularisation is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission imaging
64. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularisation
65. Molecular changes of titin in left ventricular dysfunction as a result of chronic hibernation
66. Histological alterations in chronically hypoperfused myocardium. Correlation with PET findings
67. Chronic hibernating myocardium: Interstitial changes
68. Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans
69. Myocyte degeneration and cell death in hibernating myocardium
70. Relation of the contractile reserve of hibernating myocardium to myocardial structure in humans
71. Myocardial cell death and apoptosis in hibernating myocardium
72. "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation. Analysis by immunogold electron microscopy combined with in situ nick end-labeling
73. Apoptosis in the failing human heart
74. Apoptosis in the heart
75. Efficacy of coronary angioplasty for the treatment of hibernating myocardium
76. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction